Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Regression of myocardial hypertrophy after aortic valve replacement: faster in women?

Petrov G, Regitz-Zagrosek V, Lehmkuhl E, Krabatsch T, Dunkel A, Dandel M, Dworatzek E, Mahmoodzadeh S, Schubert C, Becher E, Hampl H, Hetzer R.

Circulation. 2010 Sep 14;122(11 Suppl):S23-8. doi: 10.1161/CIRCULATIONAHA.109.927764.

PMID:
20837918
2.

Recurrent metabolic acidosis in a dialysis patient.

Elitok S, Trump S, Hampl H, Leibfritz D, Kettritz R, Luft FC.

Kidney Int. 2010 Aug;78(4):425-6. doi: 10.1038/ki.2010.180. No abstract available.

3.

Darbepoetin alfa and chronic kidney disease.

Hampl H, Kovesdy CP, Kalantar-Zadeh K.

N Engl J Med. 2010 Feb 18;362(7):654; author reply 655. No abstract available.

PMID:
20187260
4.

Cardiac disease in the dialysis patient: good, better, best clinical practice.

Hampl H, Riedel E.

Blood Purif. 2009;27(1):99-113. doi: 10.1159/000167017. Epub 2009 Jan 23. Review.

PMID:
19169026
5.

Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia.

Wiswedel I, Peter D, Gardemann A, Carluccio F, Hampl H, Siems W.

Biomark Insights. 2008 May 27;3:419-428.

6.

Optimized heart failure therapy and complete anemia correction on left-ventricular hypertrophy in nondiabetic and diabetic patients undergoing hemodialysis.

Hampl H, Hennig L, Rosenberger C, Gogoll L, Riedel E, Scherhag A.

Kidney Blood Press Res. 2005;28(5-6):353-62. Epub 2006 Mar 7.

7.

Oxysterols are increased in plasma of end-stage renal disease patients.

Siems W, Quast S, Peter D, Augustin W, Carluccio F, Grune T, Sevanian A, Hampl H, Wiswedel I.

Kidney Blood Press Res. 2005;28(5-6):302-6. Epub 2006 Mar 7.

8.

Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment.

Siems W, Carluccio F, Radenkovic S, Grune T, Hampl H.

Kidney Blood Press Res. 2005;28(5-6):295-301. Epub 2006 Mar 7.

9.

F2-isoprostanes as biomarkers of lipid peroxidation in patients with chronic renal failure.

Wiswedel I, Hirsch D, Carluccio F, Hampl H, Siems W.

Biofactors. 2005;24(1-4):201-8.

PMID:
16403981
10.

Proven strategies to reduce cardiovascular mortality in hemodialysis patients.

Hampl H, Hennig L, Rosenberger C, Gogoll L, Riedel E, Scherhag A.

Blood Purif. 2006;24(1):100-6.

11.

Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients.

Hampl H, Hennig L, Rosenberger C, Amirkhalily M, Gogoll L, Riedel E, Scherhag A.

Am J Nephrol. 2005 May-Jun;25(3):211-20. Epub 2005 May 18.

PMID:
15900093
12.

Oxidative stress in cardio renal anemia syndrome: correlations and therapeutic possibilities.

Siems W, Quast S, Carluccio F, Wiswedel I, Hirsch D, Augustin W, Kraemer K, Hampl H, Sommerburg O.

Clin Nephrol. 2003 Jul;60 Suppl 1:S22-30. Review.

PMID:
12940531
13.

Regression of left ventricular hypertrophy in hemodialysis patients is possible.

Hampl H, Sternberg C, Berweck S, Lange D, Lorenz F, Pohle C, Riedel E, Gogoll L, Hennig L.

Clin Nephrol. 2002 Jul;58 Suppl 1:S73-96.

PMID:
12227731
14.

Renal anemia and its hemodynamic response--findings invasively determined over a period of 20 years.

Schäfer GE, Rehbein C, Stiegler T, Hampl H.

Clin Nephrol. 2002 Jul;58 Suppl 1:S52-7.

PMID:
12227727
15.

Homocysteine in chronic renal failure in relation to renal anemia and to oxidative stress parameters 4-hydroxynonenal and malondialdehyde.

Carluccio F, Siems W, Stefanelli G, Sommerburg O, Grune T, Riedel E, Hampl H.

Clin Nephrol. 2002 Jul;58 Suppl 1:S26-30.

PMID:
12227723
16.

Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia.

Siems W, Carluccio F, Grune T, Jakstadt M, Quast S, Hampl H, Sommerburg O.

Clin Nephrol. 2002 Jul;58 Suppl 1:S20-5.

PMID:
12227722
17.

Why correct renal anemia completely?

Hampl H.

Clin Nephrol. 2000 Feb;53(1 Suppl):S87-9. No abstract available.

PMID:
10746812
18.

Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.

Berweck S, Hennig L, Sternberg C, Dingerkus H, Ludat K, Hampl H.

Clin Nephrol. 2000 Feb;53(1 Suppl):S80-5.

PMID:
10746811
19.
20.

Amino acid and alpha-keto acid metabolism depends on oxygen availability in chronic hemodialysis patients.

Riedel E, Nündel M, Wendel G, Hampl H.

Clin Nephrol. 2000 Feb;53(1 Suppl):S56-60.

PMID:
10746807
21.

Complete correction of renal anemia by recombinant human erythropoietin.

Ludat K, Paulitschke M, Riedel E, Hampl H.

Clin Nephrol. 2000 Feb;53(1 Suppl):S42-9.

PMID:
10746805
22.

Long-term effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits.

Paulitschke M, Ludat K, Riedel E, Hampl H.

Clin Nephrol. 2000 Feb;53(1 Suppl):S36-41.

PMID:
10746804
23.

Oxidation parameters in complete correction of renal anemia.

Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H.

Clin Nephrol. 2000 Feb;53(1 Suppl):S30-5.

PMID:
10746803
24.

Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?

Sommerburg O, Grune T, Hampl H, Riedel E, Ehrich JH, Siems WG.

Clin Nephrol. 2000 Feb;53(1 Suppl):S23-9.

PMID:
10746802
25.

Long-term renal replacement therapy.

Hampl H.

Clin Nephrol. 2000 Feb;53(1 Suppl):S1. No abstract available.

PMID:
10746798
26.

Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure.

Hampl H, Steinmüller T, Fröhling P, Naoum C, Leder K, Stabell U, Schnoy N, Jehle PM.

Miner Electrolyte Metab. 1999 May-Jun;25(3):161-70.

PMID:
10436401
27.

Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?

Sommerburg O, Grune T, Hampl H, Riedel E, van Kuijk FJ, Ehrich JH, Siems WG.

Nephrol Dial Transplant. 1998 Oct;13(10):2583-7.

PMID:
9794564
28.

Emerging viral pathogens in long-term expatriates (I): Hepatitis E virus.

Jänisch T, Preiser W, Berger A, Mikulicz U, Thoma B, Hampl H, Doerr HW.

Trop Med Int Health. 1997 Sep;2(9):885-91.

29.

Update on HIV-1 group O infection in Equatorial Guinea, Central Africa.

Zekeng L, Obiang Sima J, Hampl H, Ndemesogo JM, Ntutumu J, Sima V, Devare S, Kaptue L, Gürtler L.

AIDS. 1997 Sep;11(11):1410-2. No abstract available.

PMID:
9302460
30.

Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.

Hunt JC, Golden AM, Lund JK, Gürtler LG, Zekeng L, Obiang J, Kaptué L, Hampl H, Vallari A, Devare SG.

AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):995-1005.

PMID:
9264286
31.

Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection.

Prohászka Z, Nemes J, Hidvégi T, Tóth FD, Kerekes K, Erdei A, Szabó J, Ujhelyi E, Thielens N, Dierich MP, Späth P, Ghebrehiwet B, Hampl H, Kiss J, Arlaud G, Füst G.

AIDS. 1997 Jul;11(8):949-58.

PMID:
9223728
32.

Sequence of gp41env immunodominant region of HIV type 1 group O from west central Africa.

Brennan CA, Hackett J Jr, Zekeng L, Lund JK, Vallari AS, Hickman RK, Gürtler L, Kaptue L, Von Overbeck J, Hampl H, Devare SG.

AIDS Res Hum Retroviruses. 1997 Jul 1;13(10):901-4.

PMID:
9197385
33.

Molecular analyses of HIV-1 group O and HIV-2 variants from Africa.

Hunt JC, Brennan CA, Golden AM, Yamaguchi J, Lund JK, Vallari AS, Hickman RK, Zekeng L, Gürtler LG, Hampl H, Kaptué L, Devare SG.

Leukemia. 1997 Apr;11 Suppl 3:138-41.

PMID:
9209322
34.

Ligase chain reaction (LCR) assay for semi-quantitative detection of HBV DNA in mononuclear leukocytes of patients with chronic hepatitis B.

Trippler M, Hampl H, Goergen B, Spies U, Knolle P, Grimm B, Meyer zum Büschenfelde KH, Gerken G.

J Viral Hepat. 1996 Sep;3(5):267-72.

PMID:
8914008
35.

Demonstration of specific detection of anti-HCV IgM core antibodies.

Kapprell HP, Michel G, Hampl H, Bonino F, Esteban JI.

J Virol Methods. 1996 May;59(1-2):121-6.

PMID:
8793838
36.

alpha-Ketoglutarate application in hemodialysis patients improves amino acid metabolism.

Riedel E, Nündel M, Hampl H.

Nephron. 1996;74(2):261-5.

PMID:
8893139
37.

Calcium alpha-ketoglutarate administration to malnourished hemodialysis patients improves plasma arginine concentrations.

Riedel E, Hampl H, Steudle V, Nündel M.

Miner Electrolyte Metab. 1996;22(1-3):119-22.

PMID:
8676801
38.

Hepatitis E in Ireland.

Lynch M, O'Flynn N, Cryan B, Hampl H, Opstelten R.

Eur J Clin Microbiol Infect Dis. 1995 Dec;14(12):1109. No abstract available.

PMID:
8681992
39.

First case of HIV-1 subtype 0 infection in Germany.

Hampl H, Sawitzky D, Stöffler-Meilicke M, Groh A, Schmitt M, Eberle J, Gürtler L.

Infection. 1995 Nov-Dec;23(6):369-70. No abstract available.

PMID:
8655208
40.

Hepatitis E virus: no evidence of parenteral transmission in Finland.

Pohjanpelto P, Ebeling F, Rasi V, Hampl H.

Thromb Haemost. 1995 Nov;74(5):1385-6. No abstract available.

PMID:
8607132
41.

Detection of specific human immunodeficiency virus IgM antibodies.

Hampl H, Kapprell HP, Sawitzky D, Wilske W, Gürtler L.

Med Microbiol Immunol. 1995 Aug;184(2):69-71.

PMID:
7500913
42.

Hepatitis E in patients with chronic autoimmune liver disease.

Sylvan SP, Hellstrom UB, Hampl H, Kapprell HP, Troonen H.

JAMA. 1995 Feb 1;273(5):377-8. No abstract available.

PMID:
7823381
43.
44.

HCV core IgM and IgG antibodies in blood donors.

Kapprell HP, Majnak A, Medgyesi GA, Szabó JE, Michel G, Albrecht M, Heyermann H, Hampl H, Troonen H.

Vox Sang. 1995;68(1):57-8. No abstract available.

PMID:
7536991
45.

New tools for HCV confirmation.

Claeys H, Verhaert H, Liang Z, Vermylen C, Opstelten R, Hampl H.

Vox Sang. 1995;69(1):76-7. No abstract available.

PMID:
7483499
46.

Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41.

Hidvégi T, Prohászka Z, Ujhelyi E, Thielens NM, Dierich MP, Hampl H, Arlaud G, Nagy K, Füst G.

Clin Exp Immunol. 1993 Dec;94(3):490-3.

47.

[Comments on HIV antigen screening of blood donors].

Baumgarten K, Chiewsilp P, Gilcher R, Gürtler L, Hampl H, Henrard D, Holzberger G, Jullien AM, Kühnl P, Matthes G, et al.

Infusionsther Transfusionsmed. 1993 Jun;20(3):96-8. German. No abstract available.

PMID:
8364335
48.

Changed purine nucleotide concentrations and enzyme activities in erythrocytes of haemodialysis patients undergoing erythropoietin therapy.

Siems W, Grune T, Hampl H, Wendel G, Gerber G, Riedel E.

Eur J Clin Chem Clin Biochem. 1992 Aug;30(8):455-60.

PMID:
1445958
49.

Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific.

Krämer A, Biggar RJ, Hampl H, Friedman RM, Fuchs D, Wachter H, Goedert JJ.

Am J Epidemiol. 1992 Jul 1;136(1):71-80.

PMID:
1384311
50.

Severity of anaemia influences pattern of amino acids and alpha-keto acids in haemodialysis patients.

Riedel E, Hampl H, Nündel M, Busche D, Fuchs H.

Contrib Nephrol. 1992;98:98-104. No abstract available.

PMID:
1493738

Supplemental Content

Support Center